

Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells

Ofer Regev^{1,2}, Noa Kidan^{1,3}, Meshel Nicola^{1,2}, Hazem Khamisie¹, Martin Ruthardt⁴, Jamal Mahajna^{1,2}

¹Department of Nutrition and Natural Products, Migal-Galilee Research Institute, Kiryat Shmona, Israel

²Department of Biotechnology, Tel Hai College, Kiryat Shmona, Israel

³Department of Nutritional Sciences, Tel Hai College, Kiryat Shmona, Israel

⁴Department of Hematology, Division of Cancer and Genetics, and Experimental Clinical Medical Center (ECMC), Medical School, Cardiff University, Cardiff, United Kingdom

Submitted: 6 June 2020

Accepted: 27 September 2020

Arch Med Sci 2021; 17 (1): 266–274

DOI: <https://doi.org/10.5114/aoms.2020.101042>

Copyright © 2020 Termedia & Banach

Corresponding author:

PhD Jamal Mahajna
Department of Nutrition
and Natural Products
Migal-Galilee
Research Institute
Department of
Nutrition Sciences
Tel Hai College, Israel
E-mail: Jamalm@migal.org.il

Chronic myelogenous leukemia (CML) is characterized by a t(9;22) chromosome translocation (Philadelphia chromosome-positive [Ph⁺]) that creates the BCR/ABL oncogene. This fusion protein displays constitutive tyrosine kinase activity, leading to the induction of aberrant proliferation and neoplastic transformation [1]. The Ph⁺ chromosome is found in more than 95% of CML and in Ph⁺ acute lymphoblastic leukemia.

ABL tyrosine kinase inhibitors (AKIs) are utilized for the treatment of Ph⁺ leukemia; the initial response is beneficial [2–4] but unfortunately, the clinical efficacy of this treatment decreases steadily as the disease progresses [5]. CML blast crisis or Ph⁺ acute lymphoblastic leukemia patients only benefit from TKI treatment temporarily, if at all [6, 7].

Resistance to drug therapy in Ph⁺ leukemia is mediated by mutations within BCR/ABL or by BCR/ABL-independent mechanisms, such as tumor microenvironment-mediated drug resistance [8]. The bone marrow (BM) plays a vital role in hematopoiesis, as well as in different aspects of disease progression in hematological malignancies [8, 9]. The BM microenvironment is also critical for long-term hematopoiesis, and for the maintenance and regulation of stem cells and their progeny [9]. It is a rich source of paracrine- and autocrine-derived factors which have also been implicated in drug resistance for both hematologic malignancies and solid tumors that metastasize to the BM [10–12]. Conditions within the BM niche, including soluble factors (SFs), interleukins (ILs), stromal cells, and extracellular components, contribute to reduced drug sensitivity of cancer cells [10, 13, 14], including drug resistance to multiple TKIs, such as imatinib, nilotinib, and dasatinib [15–19].

To explore the BCR/ABL-independent mechanisms underlying Ph⁺ leukemia drug resistance, we investigated the ability of SFs collected from mesenchymal stem cells (MSCs) to confer drug resistance in CML cell lines *in vitro*. Exposure of CML cells to mesenchymal SFs conferred resistance to imatinib, but not crizotinib, which was mediated in part by the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway. Inhibition of JAK2 by ruxolitinib restored sensitivity to imatinib in CML cells exposed to mesenchymal SFs. Moreover, the multi-TKI crizotinib, which has been reported to also inhibit ABL tyrosine kinase

activity, was also able to abrogate JAK2 activity, thereby overcoming SF-mediated drug resistance in Ph⁺ leukemia.

Blast crisis human chronic myelogenous leukemia cell line K562 and megakaryocytic leukemia cell line MEG-01 (American Type Culture Collection (ATCC), VA, USA), and Ba/F3 JAK2 V617F cells expressing activated JAK2 and harboring the V617F mutation, have been described previously [20]. Cells were cultured in RPMI 1640 complete medium supplemented with 10% (w/v) fetal bovine serum, 1% (w/v) L-glutamine, and penicillin/streptomycin. The human and murine stromal cells HS-5 and MS-5, respectively (ATCC), were maintained under the same conditions. All cells were grown at 37°C in a humidified atmosphere with 5% CO₂.

HS-5 or MS-5 cells were grown in complete RPMI medium and CM were collected after 72 h. Contaminating cells were cleared by centrifugation at 1,000 rpm for 1 min; the collected supernatant was used fresh in each experiment.

Cells (2×10^5 /well) were plated in six-well plates. After 24 h, cells were treated with the specified agents. Solvent-treated samples were incubated with 1% (w/v) dimethyl sulfoxide. Cells were collected 72 h later, stained with 0.4% (w/v) trypan blue solution (1 : 1, v/v), and counted using a hemacytometer [20].

Cytokine levels were measured in the CM of MS-5 cells using mouse cytokine array panel A (Proteome Profiler Array, R&D Systems, MN, USA). Briefly, CM were mixed with a cocktail of biotinylated detection antibodies. The CM-antibody mixture was then incubated with the mouse cytokine array membrane. Following a wash to remove unbound material, streptavidin conjugated to horseradish peroxidase and chemiluminescent detection reagents were added sequentially. Data were visualized using X-ray film. Optical densities were determined using ImageJ software.

Clonogenicity assay was performed as previously described [21]. The plates were stained for 4 h with 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, and the dye was extracted with solubilization buffer (20% w/v sodium dodecyl sulfate (SDS), 50% w/v N,N-dimethylformamide, 25 mM HCl) for 24 h. Optical density was measured at 570 nm with a reference wavelength of 630 nm.

Immunoblotting was performed as described previously [22]. Anti-pSTATs (phosphor-Stat antibody sampler kit cat #9914), anti-JAK2 (cat #3230), anti-pJAK2 (Tyr 1007/1008)(cat #3776), anti-phosphor Abl (Tyr 245) (cat #2861) and anti-cleaved PARP (cat #5625) antibodies were from Cell Signaling Technology (MA, USA). Anti-PARP (cat #SC-8007) antibodies were from Santa Cruz Biotechnology (CA, USA).




Figure 1. Mesenchymal stem cell (MSC) conditioned medium (CM) confers drug resistance to imatinib in CML cells. **A** – MEG-01 and K562 cells were exposed to increasing concentrations of CM (0, 6.25, 12.5, 25%) collected from MS-5 or HS-5, and viability of remaining cells after treatment with 1 μ M imatinib for 72 h was determined. CM collected from MS-5 or HS-5 supplied to MEG-01 and K562, respectively. **B** – MEG-01 and K562 cells were exposed to 12.5% CM collected from MSC cells in the presence or absence of 1 μ M imatinib for 72 h. Negative control – 12.5% RPMI medium +1% FCS. ***Significantly different from untreated cells at $p < 0.01$ and 0.001, respectively. The experiment was repeated twice, with a comparable outcome

Student's *t*-test was used for the statistical analyses, with the significance level set at $p < 0.01$ or $p < 0.001$.

To address drug sensitivity of CML cell lines to AKIs in the presence of CM collected from MSC cells, we utilized human K562 [23] and MEG-01 cells [24] as an *in-vitro* model of CML. We followed the effect of imatinib on proliferation and triggering of PARP cleavage as a marker of apoptosis induction [25] in MEG-01 CML cells in the presence and absence of CM collected from MS-5 cells. Exposure of MEG-01 cells to various concentrations of MS-5 CM (6.25–25%) resulted in increased cell survival in the presence of imatinib (Figure 1 A). In fact, as little as 3% MS-5 CM was sufficient to confer partial drug resistance in MEG-01 cells treated with imatinib (data not shown). Next, we measured the effect of MS-5 CM on imatinib-induced growth inhibition using K562 and MEG-01 CML cells. MS-5 CM protected cells of both CML lines from imatinib-induced growth inhibition, albeit with varying potency. Overall, the magnitude of the drug resistance observed in MEG-01 cells was more than 2-fold greater than that in K562 cells (Figure 1 B). This suggested that murine SFs are active against human CML cells, although the basis for the different responses of K562 and MEG-01 cells to MS-5 CM is unclear. Nevertheless, we chose to further focus on drug sensitivity of MEG-01 cells in response to exposure to MS-5 CM.

We asked whether CM collected from other cells might promote resistance to imatinib in MEG-01 cells. CM collected from A2780 and B16-F10 cell lines were not efficient at conferring drug resistance to imatinib (Supplementary Figure S1 A). Additional data (Supplementary Figure S1 B) supported involvement of SFs, but not microvessels, as mediators of drug resistance in CML exposed to MSC CM [26].

We recently demonstrated that crizotinib, an anaplastic lymphoma kinase (ALK)/ROS1 inhibitor [27, 28], efficiently and selectively suppresses growth of Ph⁺ cells, and inhibits activity of native and T315I-mutated BCR/ABL [29, 30]. Here, we also explored the ability of CM collected from MSCs to induce drug resistance in MEG-01 cells exposed to crizotinib. Figure 2 shows that MS-5 CM conferred significant drug resistance to imatinib in MEG-01 cells, but had a minimal protective effect in cells exposed to either ponatinib [31] or crizotinib (Figure 2 A). Next, we monitored the ability of MSC CM to interfere with imatinib- and crizotinib-induced apoptosis of MEG-01 cells. Initially, MEG-01 cells were treated with crizotinib or imatinib for 24 h in the presence or absence of MS-5 CM. Exposure to imatinib/crizotinib significantly increased the levels of cleaved PARP enzyme (Figure 2 B) [25]. Interestingly, the presence of MS-5 CM prevented PARP cleavage,

again suggesting that it confers drug resistance to imatinib in MEG-01 cells (Figure 2 B). In contrast, exposure of MEG-01 cells to crizotinib resulted in significant cleavage of PARP, indicating induction of apoptosis (Figure 2 B). Next, we examined the effect of MS-5 CM on the activity of BCR/ABL in MEG-01 cells exposed to imatinib or crizotinib. Data presented in Figures 2 C and D show that imatinib was active in inhibiting BCR/ABL auto-phosphorylation in the presence and absence of MS-5 CM. In addition, the high concentration of crizotinib was active at inhibiting BCR/ABL auto-phosphorylation, but showed only marginal activity at the low concentration, in the presence and absence of MS-5 CM. Imatinib was active at inducing PARP cleavage in MEG-01 cells, and induction of PARP cleavage was largely reduced (by about 50%) in the presence of MS-5 CM. In contrast, crizotinib induction of PARP cleavage was not reduced, but rather enhanced in the presence of MS-5 CM. Thus, the apoptosis-inducing activity of imatinib, but not of crizotinib, was reduced in the presence of MS-5 CM with no significant change in imatinib's ability to inhibit BCR/ABL auto-phosphorylation.

To identify potential SFs in the MS-5 CM that are involved in mediating drug resistance to imatinib, we monitored the levels of a variety of SFs using a cytokine array assay kit. Figures 3 A and B shows a number of cytokines and ILs, in particular IL-3 and IL-17 (Figures 3 A, B), that were present at high levels in the MS-5 CM, whereas others, such as IL-1R α and IL-12 p70, were present at low levels (Figures 3 A, B). We hypothesized that one or a few cytokines are involved in mediating imatinib drug resistance in CML cells, and we selected IL-3 to further investigate this. Increasing concentrations of murine IL-3 conferred resistance to imatinib in MEG-01 cells in a dose-dependent manner (Figure 3 C).

JAK/STAT pathways are downstream regulators of a number of ILs, such as IL-6 and IL-3, which have also been implicated in drug resistance in CML [15, 32, 33]. Moreover, emerging data also implicate the JAK/STAT pathway in BM-mediated drug resistance [15, 16, 19]. Thus, we investigated the involvement of the JAK/STAT pathway in the observed imatinib resistance in CML cells exposed to MS-5 CM. MEG-01 cells were exposed to MSC CM and levels of various phosphorylated STATs were monitored.

The levels of both pSTAT1 and pSTAT2 were undetectable in the MEG-01 cells, with no change after exposure to either MS-5 CM (Figure 4 A) or HS-5 CM (data not shown). Moreover, STAT6 and STAT3 were not phosphorylated in MEG-01 cells, and exposure to MS-5 or HS-5 CM significantly stimulated their phosphorylation levels. In contrast, STAT5, which is a direct downstream target of BCR/ABL [34–36], was significantly phosphory-

lated in MEG-01 cells and the phosphorylation levels were further increased upon exposure to both HS-5 and MS-5 CM (Figure 4 A).

STATs are downstream transcription factors that are activated by JAKs in response to cytokine

activation. Thus, we investigated the influence of JAK inhibitors on imatinib resistance mediated by MS-5 CM. Figure 4 B shows the viability of MEG-01 cells exposed to MS-5 CM in the presence of imatinib and the clinically approved JAK1/2 inhibitor




Figure 2. Crizotinib overcomes mesenchymal stem cell (MSC) conditioned medium (CM)-mediated drug resistance. **A** – MEG-01 cells were exposed to 1 μM imatinib, ponatinib or crizotinib in the presence or absence of 12.5% HS-5 CM and the number of viable cells was counted after 72 h exposure. **B** – MEG-01 cells were exposed to 1 μM imatinib, ponatinib or crizotinib in the presence or absence of 12.5% MS-5 CM and the number of viable cells was counted after 72 h exposure. **C** – Immunoblot of MEG-01 cells exposed to 1 μM imatinib or crizotinib in the presence or absence of MS-5 CM. In addition, 1 μM imatinib or crizotinib was added to MEG-01 cells co-cultured with MS-5 cells. Filters were probed with anti-cleaved (c)-PARP antibody and α-tubulin was used as a loading control. **D** – Immunoblot of K562 cells exposed to 0.5 μM and 2 μM imatinib or crizotinib in the presence or absence of MS-5 CM. Filters were probed with anti-c-PARP antibody, anti-phospho Abl (Tyr 245) and anti-GAPDH was used as a loading control. **E** – Quantitation of experiment in D showing relative levels of cleaved PARP and phospho BCR/ABL (relative to GAPDH). *Significantly different from untreated cells at $p < 0.01$. The experiment was repeated twice, with a comparable outcome

ruxolitinib [37]. As expected, exposure of MEG-01 cells to MS-5 CM conferred drug resistance to imatinib, but not crizotinib. When ruxolitinib was added along with imatinib, MEG-01 sensitivity to the latter was partially restored (Figure 4 B), supporting the involvement of JAK1/2 in mediating the MSC CM-induced drug resistance. Further support for the ability of ruxolitinib to restore sensitivity to imatinib in the presence of MS-5 CM was provided by following the levels of cleaved PARP in MEG-01 cells treated with imatinib, crizotinib, ruxolitinib, or imatinib + ruxolitinib in the presence and absence of MS-5 CM. Imatinib and crizotinib induced PARP cleavage in MEG-01 cells. However, no PARP cleavage was observed in MEG-01 cells treated with either imatinib or ruxolitinib alone in the presence of MS-5 CM (Figure 4 C). On the other hand, ruxolitinib + imatinib effectively caused significant PARP cleavage, indicating restoration of partial sensitivity of MEG-01 cells to imatinib in the presence of MS-5 CM (Figure 4 C).

Data presented in Figures 4 B and C show that inhibition of JAK1/2 (by ruxolitinib) can restore sensitivity to imatinib in CML cells exposed to MS-5 CM. We therefore speculated that crizotinib's ability to overcome mesenchymal SF-me-

diated drug resistance in CML might be related to JAK1/2 activity. To address this point, we utilized a Ba/F3 model system in which cells become IL-3-independent upon introduction of activated JAK2 (JAK2 V617F) [20]. Use of this system allowed us to monitor the direct effect of crizotinib on JAK2 activity. Initially, we monitored the effects of crizotinib and other relevant TKIs on the clonogenicity of Ba/F3 JAK2 V617F cells. Figures 5 A and B shows that the colony-forming ability of Ba/F3 JAK2 V617F cells was not affected by imatinib or other ABL inhibitors such as GNF-2 or GNF-5 [38]. However, crizotinib inhibited clonogenicity of Ba/F3 JAK2 V617F cells with a potency comparable to that of ruxolitinib. Interestingly, ponatinib was also a potent inhibitor of Ba/F3 JAK2 V617F clonogenicity.

Next, we utilized the same cells to monitor direct inhibition of JAK2 auto-phosphorylation by crizotinib. Ruxolitinib actively inhibited auto-phosphorylation of JAK2 V617F, and crizotinib also exhibited strong inhibition of JAK2 auto-phosphorylation. In contrast, neither imatinib nor GNF-5 inhibited JAK2 auto-phosphorylation (Figures 5 C, D).

CML-targeted therapy has proven to be very effective in managing the disease and has led to ex-




Figure 3. Identification of soluble factors (SFs) in MS-5 conditioned medium (CM) as potential mediators of imatinib resistance in MEG-01 cells. CM was collected from MS-5 cells after 72 h of culture. **A** – Immunoblot test for relative expression levels of 40 factors in MS-5 CM was carried out according to the manufacturer's instructions. **B** – Optic absorption was measured by TINA software and levels of soluble factors in MS-5 CM relative to RPMI are presented. **C** – Cell viability (number of remaining cells) of K562 cells treated with 1 μ M imatinib and increasing concentrations of murine (m) IL-3 for 72 h was determined. *Significantly different from untreated cells at $p < 0.01$. The experiment was repeated twice, with a comparable outcome

tended lifespans for many CML patients. However, about 30% of those patients fail to respond, respond suboptimally, or experience disease relapse after treatment with CML-targeted therapy due, in part, to drug resistance [5, 39]. In general, Ph⁺ leukemia resistance to drug therapy might be due to mutations in the cancer cells, including alterations in the BCR/ABL fusion gene, or associated with interactions between Ph⁺ leukemia cancer cells and the BM microenvironment, leading to tumor microenvironment-mediated drug resistance and consequently a low level of residual disease and disease progression [8].

Intensive effort has been invested in developing strategies to address drug resistance in Ph⁺ leukemia by introducing new TKIs that are active against ABL1 mutations, including the gatekeeper T315I mutation [40]. Moreover, effort is still being made to target additional regulatory elements within the ABL1 kinase, such as the myristoyl-binding pocket in the BCR/ABL protein [20, 41], or to use a drug combination [21, 42].

The BM microenvironment contributes significantly to drug resistance in both hematologic malignancies and solid tumors that metastasize to the BM [10–12]. Conditions in the BM niche that contribute to reduced drug sensitivity might in-

clude SFs, stromal cells, and extracellular components [10, 13, 14, 43]. Thus, modulation of signaling pathways involved in mediating the interaction, adhesion, or homing of hematopoietic cancer cells to BM stromal cells is expected to influence drug sensitivity in hematopoietic malignancies [13–16].

The BM microenvironment-mediated drug resistance might be due to SFs or to cell adhesion to the microenvironment compartment. To address BM microenvironment-mediated drug resistance, we monitored the ability of CM collected from MSCs to affect the sensitivity of CML cells to imatinib and crizotinib. We monitored the viability of CML cells as well as induction of PARP cleavage (Figures 1, 2), a marker of apoptosis induction [25].

MEG-01 cells were sensitive to imatinib and crizotinib as evidenced by inhibition of CML cell viability (Figures 1 A, B) and induction of PARP cleavage (Figures 2 B, C). However, CM collected from MSCs conferred resistance to imatinib, consistent with previous observations [16]. Interestingly, MEG-01 cells were more sensitive to MS-5 CM than K562 cells. The presence of CM from MSCs reduced the sensitivity of the CML cells to imatinib-induced apoptosis, but not to crizotinib, suggesting that mesenchymal SFs can promote imatinib resistance with continued sensitivity to




Figure 4. MS-5 conditioned medium (CM) stimulates JAK/STAT pathway in MEG-01 cells. **A** – MEG-01 cells exposed to 12.5% CM collected from MS-5 and HS-5 cultures were used to monitor levels of activated STATs by immunoblotting. MEG-01 cells were seeded and exposed to 12.5% CM from MS-5/HS-5 cells for 2 h. Cells were collected, and the phosphorylation of STAT3/4/6 was monitored by immunoblotting. Tubulin was used as a loading control. **B** – MEG-01 cell viability was monitored after exposure to 12.5% MS-5 CM in the presence of 1 μ M imatinib, imatinib + ruxolitinib or crizotinib alone. Cell viability was monitored 72 h after treatment. **C** – Ability of different kinase inhibitors to induce apoptosis in MEG-01 cells in the presence of MS-5 CM. MEG-01 cells were treated with 1 μ M of the different Abl kinase inhibitors in the presence or absence of 12.5% CM for 24 h. The complete PARP protein (120 kDa) was used as a positive control. ***Significantly different from untreated cells at $p < 0.01$ and 0.001 , respectively. The experiment was repeated twice, with a comparable outcome

the activity of crizotinib (Figure 2). We speculated that drug resistance stimulated by the CM is mediated by SFs secreted by the MSCs. We identified a number of SFs that were present in significant amounts in the CM, such as IL-3, IL-1R α , IL-17 and IL-12 p70, and speculated that one or a combination of these is responsible for mediating imatinib resistance in CML cells. Our speculation was supported by previous reports showing that IL-7 secreted by MSCs in the BM might protect leukemic cells from apoptosis induced by imatinib through

the JAK/STAT-signaling pathway [44]. In addition, Jiang *et al.* [45] demonstrated autocrine production and activity of IL-3 and granulocyte colony-stimulating factor (G-CSF) in CML [45]. Moreover, culturing K562 cells with HS-5-derived CM significantly inhibited apoptosis induced by imatinib via a STAT3-dependent mechanism [18], and imatinib sensitivity was restored by exposure to STAT3 inhibitor [46]. Our results are also corroborated by Zhang *et al.* [43], who found that CML stem cells demonstrate increased IL-1 receptor expression




Figure 5. Crizotinib inhibits JAK2 activity. **A** – Ba/F3 JAK2 V617F cells were used to monitor different kinase inhibitors' effects on clonogenicity as described in Material and methods. **B** – Areas of each sample were determined by monitoring absorbance using Image J and values obtained in samples treated with 0.1 μ M and 1 μ M kinase inhibitor were plotted. **C** – Ba/F3 JAK2 V617F cells were exposed for 1 h to different concentrations of imatinib, crizotinib (1, 3 and 10 μ M) or GNF-5 (3 and 10 μ M). Ruxolitinib at 1 μ M was used as a positive control. Cells were collected and lysed and their proteins were separated by SDS-PAGE. Levels of pJAK2 were monitored relative to JAK2 and α -tubulin was used as a loading control. **D** – Levels of pJAK2 relative to α -tubulin. The experiment was repeated twice, with a comparable outcome

and an enhanced signaling response; however, inhibition of IL-1 signaling when combined with TKIs enhanced anti-CML efficacy. In our study, we also monitored levels of activated STAT proteins and found that the presence of MSC CM results in activation of STAT3 and STAT6 (Figure 4). Increased activation of STAT3 has been associated with malignant cell transformation and drug-resistant tumors [44, 46, 47]. Moreover, exposure of CML cells to MSC CM caused an increase in pSTAT3 and consequently increased the expression of STAT3-regulated genes such as Bcl-xl, Mcl-1, and survivin [46]. Thus, we argue that exposure to SFs that stimulate activation of STAT3 or STAT6 promotes the expression of a variety of antiapoptotic genes [48, 49], and hence promotes drug resistance.

JAK family kinases are the upstream activators of STAT proteins and also participate in mediating the function of a variety of cytokines [50]. Thus, we monitored the ability of the JAK1/2 inhibitor ruxolitinib [37] to abolish the drug resistance mediated by MSC CM. The presence of ruxolitinib restored partial imatinib sensitivity in CML cells exposed to MSC CM. Our results are consistent with data reported by Mencilha *et al.* [51] showing that STAT3 inhibitor has an additive effect with imatinib in inducing apoptosis in CML cells, suggesting a potential therapeutic value to combining these two drug regimens for the treatment of CML patients. Moreover, evidence for the potential of drug combinations in CML therapy was also provided by Ma *et al.* [52], who showed inhibition of growth and proliferation, cell-cycle blockade, and induction of apoptosis in K562 cells transduced with STAT3 siRNA. Thus, the use of two components was recommended to overcome SF-mediated drug resistance: one to inhibit BCR/ABL and the other to inhibit JAK1/2 activity. However, with the approval of multitarget kinase inhibitors, one might select those that are capable of inhibiting both relevant targets. Previously, we demonstrated that crizotinib efficiently inhibits kinase activity of native and T315I-mutated BCR/ABL [29]. In this study, we also found that crizotinib inhibits JAK2 activity. However, crizotinib activity against JAK1 remains to be determined. Crizotinib's ability to inhibit JAK2 enables it to overcome JAK2-dependent SF-mediated drug resistance. Similarly, ponatinib as a multi-kinase inhibitor was active in overcoming SF-mediated drug resistance in MEG-01, in part by targeting JAK2 activity, probably indirectly (Figure 5). The exact mechanism by which ponatinib inhibited clonogenicity of Ba/F3 JAK2 V617F remains to be elucidated.

In conclusion, the study showed that SFs secreted from MSC, such IL-3 and IL-7, among others, are capable of activating the JAK/STAT pathway and consequently compromise the apoptosis-inducing

activity of imatinib targeting CML cells. On the other hand, the multi-kinase inhibitor crizotinib, an FDA-approved drug for ALK-positive non-small cell lung carcinoma targeting ALK kinase, was found to inhibit BCR/ABL kinase activity and is also active in inhibiting JAK2. Exposure to crizotinib actively overcame drug resistance in CML mediated by SFs secreted from MSC. Our results raise the possibility of therapeutic use of crizotinib for CML patients who also require a JAK2 inhibitor to overcome BM microenvironment-mediated drug resistance.

References

1. Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. *N Engl J Med* 1999; 341: 164-72.
2. Ottmann OG, Hoelzer D. The ABL tyrosine kinase inhibitor ST1571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia – promises, pitfalls and possibilities. *Hematol J* 2002; 3: 2-6.
3. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. *Proc Natl Acad Sci USA* 2006; 103: 2794-9.
4. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. *Blood* 2002; 99: 1928-37.
5. Singh VK, Coumar MS. Chronic myeloid leukemia: existing therapeutic options and strategies to overcome drug resistance. *Mini Rev Med Chem* 2019; 19: 333-45.
6. Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. *Lancet Oncol* 2003; 4: 75-85.
7. Haznedaroglu IC. Drug therapy in the progressed CML patient with multi-TKI failure. *Mediterr J Hematol Infect Dis* 2015; 7: e2015014.
8. Nair RR, Tolentino J, Hazlehurst LA. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. *Biochem Pharmacol* 2010; 80: 602-12.
9. Perrotti D, Silvestri G, Stramucci L, et al. Cellular and molecular networks in chronic myeloid leukemia: the leukemic stem, progenitor and stromal cell interplay. *Curr Drug Targets* 2017; 18: 377-88.
10. Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. *Clin Cancer Res* 2008; 14: 2519-26.
11. Katz BZ, Polliack A. Cancer microenvironment, extracellular matrix, and adhesion molecules: the bitter taste of sugars in chronic lymphocytic leukemia. *Leuk Lymphoma* 2011; 52: 1619-20.
12. Witz IP. The tumor microenvironment: the making of a paradigm. *Cancer Microenviron* 2009; 2 Suppl 1: 9-17.
13. Tesfai Y, Ford J, Carter KW, et al. Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy. *Leuk Res* 2012; 36: 299-306.
14. Zhang B, Groffen J, Heisterkamp N. Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells. *Leukemia* 2007; 21: 1189-97.
15. Shain KH, Yarde DN, Meads MB, et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. *Cancer Res* 2009; 69: 1009-15.

16. Nair RR, Tolentino JH, Argilagos RF, et al. Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML. *Leuk Res* 2012; 36: 756-63.
17. Traer E, Javidi-Sharifi N, Agarwal A, et al. Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. *Blood* 2014; 123: 1516-24.
18. Bewry NN, Nair RR, Emmons MF, et al. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance. *Mol Cancer Ther* 2008; 7: 3169-75.
19. Okabe S, Tauchi T, Katagiri S, et al. Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells. *J Hematol Oncol* 2014; 7: 37.
20. Najajreh Y, Khamaisie H, Ruimi N, et al. Oleylamine-carbonyl-valinol inhibits auto-phosphorylation activity of native and T315I mutated Bcr-Abl, and exhibits selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines. *Mol Biol Rep* 2013; 40: 2205-13.
21. Khateb M, Ruimi N, Khamisie H, et al. Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism. *BMC Cancer* 2012; 12: 563.
22. Ruimi N, Petrova RD, Agbaria R, et al. Inhibition of TNF alpha-induced iNOS expression in HSV-tk transduced 9L glioblastoma cell lines by Marasmius oreades substances through NF-kappaB- and MAPK-dependent mechanisms. *Mol Biol Rep* 2010; 37: 3801-12.
23. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. *Blood* 1975; 45: 321-34.
24. Ogura M, Morishima Y, Ohno R, et al. Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. *Blood* 1985; 66: 1384-92.
25. Hannun YA, Obeid LM. Mechanisms of ceramide-mediated apoptosis. *Adv Exp Med Biol* 1997; 407: 145-9.
26. Xu X, Zhang X, Liu Y, et al. BM microenvironmental protection of CML cells from imatinib through Stat5/ NF-kappaB signaling and reversal by Wogonin. *Oncotarget* 2016; 7: 24436-54.
27. Gandhi L, Janne PA. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. *Clin Cancer Res* 2012; 18: 3737-42.
28. Sahu A, Prabhash K, Noronha V, et al. Crizotinib: a comprehensive review. *South Asian J Cancer* 2013; 2: 91-7.
29. Mahajna J, Khamaisie H, Ruimi N, et al. Crizotinib is an allosteric ABL-inhibitor targeting both native BCR/ABL and BCR/ABL-T315I in vitro and in vivo models of PH+ leukemia. *Eur J Cancer* 2014; 50: S191-2.
30. Skora L, Jahnke W. (19)F-NMR-based dual-site reporter assay for the discovery and distinction of catalytic and allosteric kinase inhibitors. *ACS Med Chem Lett* 2017; 8: 632-5.
31. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. *Cancer Cell* 2009; 16: 401-12.
32. Dorsey JF, Cunick JM, Lanehart R, et al. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. *Leukemia* 2002; 16: 1589-95.
33. Reynaud D, Pietras E, Barry-Holson K, et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. *Cancer Cell* 2011; 20: 661-73.
34. de Groot RP, Raaijmakers JA, Lammers JW, et al. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. *Blood* 1999; 94: 1108-12.
35. Sillaber C, Gesbert F, Frank DA, et al. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. *Blood* 2000; 95: 2118-25.
36. Hantschel O, Warsch W, Eckelhart E, et al. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. *Nat Chem Biol* 2012; 8: 285-93.
37. Vaddi K, Sarlis NJ, Gupta V. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis. *Expert Opin Pharmacother* 2012; 13: 2397-407.
38. Zhang J, Adrian FJ, Jahnke W, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. *Nature* 2010; 463: 501-6.
39. Hochhaus A, Erben P, Ernst T, Mueller MC. Resistance to targeted therapy in chronic myelogenous leukemia. *Semin Hematol* 2007; 44: S15-24.
40. Bose P, Park H, Al-Khafaji J, Grant S. Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase. *Leuk Res Rep* 2013; 2: 18-20.
41. Schoepfer J, Jahnke W, Berellini G, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. *J Med Chem* 2018; 61: 8120-35.
42. Mian AA, Metodjeva A, Badura S, et al. Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I. *BMC Cancer* 2012; 12: 411.
43. Zhang B, Chu S, Agarwal P, et al. Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. *Blood* 2016; 128: 2671-82.
44. Zhang X, Tu H, Yang Y, et al. High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia. *Int J Hematol* 2016; 104: 358-67.
45. Jiang X, Lopez A, Holyoake T, et al. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. *Proc Natl Acad Sci USA* 1999; 96: 12804-9.
46. Li X, Miao H, Zhang Y, et al. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway. *Arch Toxicol* 2015; 89: 121-36.
47. Ma W, Zhang Y, Qi Y, Guo S. STAT3 promotes chronic lymphocytic leukemia progression through upregulating SMYD3 expression. *Arch Med Sci* 2019; 15: 1163-75.
48. Bhattacharya S, Ray RM, Johnson LR. STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. *Biochem J* 2005; 392: 335-44.
49. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. *Oncogene* 2013; 32: 2601-13.
50. Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. *Protein Sci* 2018; 27: 1984-2009.
51. Mencalha AL, Du Rocher B, Salles D, et al. LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate. *Cancer Chemother Pharmacol* 2010; 65: 1039-46.
52. Ma LD, Zhou M, Wen SH, et al. Effects of STAT3 silencing on fate of chronic myelogenous leukemia K562 cells. *Leuk Lymphoma* 2010; 51: 1326-36.